Skip to main content

Advertisement

SpringerLink
Log in

Alterations in body composition in acromegaly

  • Published:
Pituitary Aims and scope Submit manuscript

Abstract

Acromegaly is a condition characterized by growth hormone (GH) and insulin-like growth factor-1 (IGF-1) hypersecretion, and is associated with boney overgrowth, and soft tissue abnormalities due to anabolic, lipolytic, and sodium retaining actions of GH. GH and IGF-1 excess is associated with alterations in body composition, including an increase in body water and lean body mass, and a reduction in body fat. Achievement of biochemical control of the disease results in a reduction in body water and fat-free mass, and an increase in body fat. BMD is generally increased in acromegaly, though the anabolic effect of GH excess on bone is reduced, if not negated, by the presence of hypogonadism, particularly with regard to the trabecular compartment. Further studies are necessary to determine the effect of long-term biochemical control on bone density in subjects with acromegaly.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Bengtsson BA, Brummer RJ, Eden S, Bosaeus I (1989) Body composition in acromegaly. Clin Endocrinol (Oxf) 30:121–130 Medline

    Article  CAS  Google Scholar 

  2. Gibney J, Wolthers T, Burt MG, Leung KC, Umpleby AM, Ho KK (2007) Protein metabolism in acromegaly: differential effects of short- and long-term treatment. J Clin Endocrinol Metab 92:1479–1484 Medline. doi:10.1210/jc.2006-0664

    Article  PubMed  CAS  Google Scholar 

  3. O’Sullivan AJ, Kelly JJ, Hoffman DM, Freund J, Ho KK (1994) Body composition and energy expenditure in acromegaly. J Clin Endocrinol Metab 78:381–386 Medline. doi:10.1210/jc.78.2.381

    Article  PubMed  Google Scholar 

  4. Rau H, Fischer H, Schmidt K, Lembcke B, Althoff PH (1991) Effect of bromocriptine withdrawal in acromegaly on body composition as assessed by bioelectrical impedance analysis. Acta Endocrinol (Copenh) 125:273–279 Medline

    CAS  Google Scholar 

  5. Moller J (2003) Effects of growth hormone on fluid homeostasis. Clinical and experimental aspects. Growth Horm IGF Res 13:55–74 Medline. doi:10.1016/S1096-6374(03)00011-X

    Article  PubMed  CAS  Google Scholar 

  6. Tominaga A, Arita K, Kurisu K, Uozumi T, Migita K, Eguchi KK II, Kawamoto H, Mizoue T (1998) Effects of successful adenomectomy on body composition in acromegaly. Endocr J 45:335–342 Medline. doi:10.1507/endocrj.45.335

    Article  PubMed  CAS  Google Scholar 

  7. Hansen TB, Gram J, Bjerre P, Hagen C, Bollerslev J (1994) Body composition in active acromegaly during treatment with octreotide: a double-blind, placebo-controlled cross-over study. Clin Endocrinol (Oxf) 41:323–329 Medline

    Article  CAS  Google Scholar 

  8. Gevers EF, Loveridge N, Robinson IC (2002) Bone marrow adipocytes: a neglected target tissue for growth hormone. Endocrinology 143:4065–4073 Medline. doi:10.1210/en.2002-220428

    Article  PubMed  CAS  Google Scholar 

  9. Jorgensen JO, Moller L, Krag M, Billestrup N, Christiansen JS (2007) Effects of growth hormone on glucose and fat metabolism in human subjects. Endocrinol Metab Clin North Am 36:75–87 Medline. doi:10.1016/j.ecl.2006.11.005

    Article  PubMed  CAS  Google Scholar 

  10. Sanders EJ, Harvey S (2004) Growth hormone as an early embryonic growth and differentiation factor. Anat Embryol (Berl) 209:1–9 Medline. doi:10.1007/s00429-004-0422-1

    Article  CAS  Google Scholar 

  11. Brummer RJ, Lonn L, Bengtsson BA, Kvist H, Bosaeus I, Sjostrom L (1996) Comparison of different body composition models in acromegaly. Growth Regul 6:191–200 Medline

    PubMed  CAS  Google Scholar 

  12. Miyakawa M, Tsushima T, Murakami H, Isozaki O, Demura H, Tanaka T (1998) Effect of growth hormone (GH) on serum concentrations of leptin: study in patients with acromegaly and GH deficiency. J Clin Endocrinol Metab 83:3476–3479 Medline. doi:10.1210/jc.83.10.3476

    Article  PubMed  CAS  Google Scholar 

  13. Kaji H, Sugimoto T, Nakaoka D et al (2001) Bone metabolism and body composition in Japanese patients with active acromegaly. Clin Endocrinol (Oxf) 55:175–181 Medline. doi:10.1046/j.1365-2265.2001.01280.x

    Article  CAS  Google Scholar 

  14. Bolanowski M, Milewicz A, Bidzinska B, Jedrzejuk D, Daroszewski J, Mikulski E (2002) Serum leptin levels in acromegaly—a significant role for adipose tissue and fasting insulin/glucose ratio. Med Sci Monit 8:CR685–CR689 Medline

    PubMed  CAS  Google Scholar 

  15. Licinio J, Negrao AB, Mantzoros C et al (1998) Sex differences in circulating human leptin pulse amplitude: clinical implications. J Clin Endocrinol Metab 83:4140–4147 Medline. doi:10.1210/jc.83.11.4140

    Article  PubMed  CAS  Google Scholar 

  16. Lonnqvist F, Wennlund A, Arner P (1997) Relationship between circulating leptin and peripheral fat distribution in obese subjects. Int J Obes Relat Metab Disord 21:255–260 Medline. doi:10.1038/sj.ijo.0800394

    Article  PubMed  CAS  Google Scholar 

  17. Isozaki O, Tsushima T, Miyakawa M, Demura H, Seki H (1999) Interaction between leptin and growth hormone (GH)/IGF-I axis. Endocr J 46(Suppl):S17–S24 Medline. doi:10.1507/endocrj.46.Suppl_S17

    Article  PubMed  CAS  Google Scholar 

  18. Damjanovic SS, Petakov MS, Raicevic S et al (2000) Serum leptin levels in patients with acromegaly before and after correction of hypersomatotropism by trans-sphenoidal surgery. J Clin Endocrinol Metab 85:147–154 Medline. doi:10.1210/jc.85.1.147

    Article  PubMed  CAS  Google Scholar 

  19. Baldelli R, Durante C, D’Amico E, Diacono F, Tamburrano G, Casanueva FF (2003) Serum leptin levels in acromegalic patients before and during somatostatin analogs therapy. J Endocrinol Invest 26:1219–1224 Medline

    PubMed  CAS  Google Scholar 

  20. Tan KC, Tso AW, Lam KS (2001) Effect of Sandostatin LAR on serum leptin levels in patients with acromegaly. Clin Endocrinol (Oxf) 54:31–35 Medline. doi:10.1046/j.1365-2265.2001.01180.x

    Article  CAS  Google Scholar 

  21. Parkinson C, Whatmore AJ, Yates AP et al (2003) The effect of pegvisomant-induced serum IGF-I normalization on serum leptin levels in patients with acromegaly. Clin Endocrinol (Oxf) 59:168–174 Medline. doi:10.1046/j.1365-2265.2003.01795.x

    Article  CAS  Google Scholar 

  22. Paramo C, Fluiters E, de la Fuente J, Andrade A, Garcia-Mayor RV (2001) Monitoring of treatment success in patients with acromegaly: the value of serum insulin-like growth factor binding protein-3 and serum leptin measurements in comparison to plasma insulin-like growth factor I determination. Metabolism 50:1117–1121 Medline. doi:10.1053/meta.2001.24882

    Article  PubMed  CAS  Google Scholar 

  23. Maeda N, Shimomura I, Kishida K, et al (2002) Diet-induced insulin resistance in mice lacking adiponectin/ACRP30. Nat Med 8:731–737 Medline. doi:10.1038/nm724

    Article  PubMed  CAS  Google Scholar 

  24. Yamauchi T, Kamon J, Waki H et al (2003) Globular adiponectin protected ob/ob mice from diabetes and ApoE-deficient mice from atherosclerosis. J Biol Chem 278:2461–2468 Medline. doi:10.1074/jbc.M209033200

    Article  PubMed  CAS  Google Scholar 

  25. Matsuzawa Y, Funahashi T, Kihara S, Shimomura I (2004) Adiponectin and metabolic syndrome. Arterioscler Thromb Vasc Biol 24:29–33 Medline. doi:10.1161/01.ATV.0000099786.99623.EF

    Article  PubMed  CAS  Google Scholar 

  26. Lam KS, Xu A, Tan KC, Wong LC, Tiu SC, Tam S (2004) Serum adiponectin is reduced in acromegaly and normalized after correction of growth hormone excess. J Clin Endocrinol Metab 89:5448–5453 Medline. doi:10.1210/jc.2003-032023

    Article  PubMed  CAS  Google Scholar 

  27. Kotzmann H, Bernecker P, Hubsch P et al (1993) Bone mineral density and parameters of bone metabolism in patients with acromegaly. J Bone Miner Res 8:459–465 Medline

    Article  PubMed  CAS  Google Scholar 

  28. Silha JV, Krsek M, Hana V et al (2003) Perturbations in adiponectin, leptin and resistin levels in acromegaly: lack of correlation with insulin resistance. Clin Endocrinol (Oxf) 58:736–742 Medline. doi:10.1046/j.1365-2265.2003.01789.x

    Article  CAS  Google Scholar 

  29. Wiesli P, Bernays R, Brandle M, Zwimpfer C, Seiler H, Zapf J, Spinas GA, Schmid C (2005) Effect of pituitary surgery in patients with acromegaly on adiponectin serum concentrations and alanine aminotransferase activity. Clin Chim Acta 352:175–181 Medline. doi:10.1016/j.cccn.2004.09.022

    Article  PubMed  CAS  Google Scholar 

  30. Baum HB, Biller BM, Finkelstein JS et al (1996) Effects of physiologic growth hormone therapy on bone density and body composition in patients with adult-onset growth hormone deficiency. A randomized, placebo-controlled trial. Ann Intern Med 125:883–890 Medline

    PubMed  CAS  Google Scholar 

  31. Hoffman AR, Kuntze JE, Baptista J et al (2004) Growth hormone (GH) replacement therapy in adult-onset gh deficiency: effects on body composition in men and women in a double-blind, randomized, placebo-controlled trial. J Clin Endocrinol Metab 89:2048–2056 Medline. doi:10.1210/jc.2003-030346

    Article  PubMed  CAS  Google Scholar 

  32. Liu W, Thomas SG, Asa SL, Gonzalez-Cadavid N, Bhasin S, Ezzat S (2003) Myostatin is a skeletal muscle target of growth hormone anabolic action. J Clin Endocrinol Metab 88:5490–5496 Medline. doi:10.1210/jc.2003-030497

    Article  PubMed  CAS  Google Scholar 

  33. Battezzati A, Benedini S, Fattorini A et al (2003) Insulin action on protein metabolism in acromegalic patients. Am J Physiol Endocrinol Metab 284:E823–E829 Medline

    PubMed  CAS  Google Scholar 

  34. Heymsfield SB, Wang Z, Baumgartner RN, Ross R (1997) Human body composition: advances in models and methods. Ann Rev Nutr 17:527–558 Medline. doi:10.1146/annurev.nutr.17.1.527

    Article  CAS  Google Scholar 

  35. Pirlich M, Schutz T, Ockenga J et al (2003) Improved assessment of body cell mass by segmental bioimpedance analysis in malnourished subjects and acromegaly. Clin Nutr 22:167–174 Medline. doi:10.1054/clnu.2002.0617

    Article  PubMed  CAS  Google Scholar 

  36. Landin K, Petruson B, Jakobsson KE, Bengtsson BA (1993) Skeletal muscle sodium and potassium changes after successful surgery in acromegaly: relation to body composition, blood glucose, plasma insulin and blood pressure. Acta Endocrinol (Copenh) 128:418–422 Medline

    CAS  Google Scholar 

  37. Battezzati A, Bertoli S (2005) Alterations of protein metabolism in acromegaly. Curr Opin Clin Nutr Metab Care 8:53–59 Medline. doi:10.1097/00075197-200501000-00008

    Article  PubMed  CAS  Google Scholar 

  38. Lucidi P, Laureti S, Santoni S et al (2000) Administration of recombinant human growth hormone on alternate days is sufficient to increase whole body protein synthesis and lipolysis in growth hormone deficient adults. Clin Endocrinol (Oxf) 52:173–179 Medline. doi:10.1046/j.1365-2265.2000.00910.x

    Article  CAS  Google Scholar 

  39. Lucidi P, Lauteri M, Laureti S et al (1998) A dose-response study of growth hormone (GH) replacement on whole body protein and lipid kinetics in GH-deficient adults. J Clin Endocrinol Metab 83:353–357 Medline. doi:10.1210/jc.83.2.353

    Article  PubMed  CAS  Google Scholar 

  40. Mauras N, O’Brien KO, Welch S et al (2000) Insulin-like growth factor I and growth hormone (GH) treatment in GH-deficient humans: differential effects on protein, glucose, lipid, and calcium metabolism. J Clin Endocrinol Metab 85:1686–1694 Medline. doi:10.1210/jc.85.4.1686

    Article  PubMed  CAS  Google Scholar 

  41. Nagulesparen M, Trickey R, Davies MJ, Jenkins JS (1976) Muscle changes in acromegaly. BMJ 2:914–915 Medline

    Article  PubMed  CAS  Google Scholar 

  42. Brumback RA, Barr CE (1983) Myopathy in acromegaly. A case study. Pathol Res Pract 177:41–46 Medline

    PubMed  CAS  Google Scholar 

  43. Pickett JB, Layzer RB, Levin SR, Scheider V, Campbell MJ, Sumner AJ (1975) Neuromuscular complications of acromegaly. Neurology 25:638–645 Medline

    PubMed  CAS  Google Scholar 

  44. Kassem M, Mosekilde L, Eriksen EF (1994) Growth hormone stimulates proliferation of normal human bone marrow stromal osteoblast precursor cells in vitro. Growth Regul 4:131–135 Medline

    PubMed  CAS  Google Scholar 

  45. Nishiyama K, Sugimoto T, Kaji H, Kanatani M, Kobayashi T, Chihara K (1996) Stimulatory effect of growth hormone on bone resorption and osteoclast differentiation. Endocrinology 137:35–41 Medline. doi:10.1210/en.137.1.35

    Article  PubMed  CAS  Google Scholar 

  46. Tauchmanova L, Di Somma C, Rusciano A, Lombardi G, Colao A (2007) The role for growth hormone in linking arthritis, osteoporosis, and body composition. J Endocrinol Invest 30:35–41 Medline

    PubMed  CAS  Google Scholar 

  47. Colao A, Pivonello R, Scarpa R, Vallone G, Ruosi C, Lombardi G (2005) The acromegalic arthropathy. J Endocrinol Invest 28:24–31 Medline

    PubMed  CAS  Google Scholar 

  48. Scillitani A, Battista C, Chiodini I et al (2003) Bone mineral density in acromegaly: the effect of gender, disease activity and gonadal status. Clin Endocrinol (Oxf) 58:725–731 Medline. doi:10.1046/j.1365-2265.2003.01777.x

    Article  CAS  Google Scholar 

  49. Bolanowski M, Daroszewski J, Medras M, Zadrozna-Sliwka B (2006) Bone mineral density and turnover in patients with acromegaly in relation to sex, disease activity, and gonadal function. J Bone Miner Metab 24:72–78 Medline. doi:10.1007/s00774-005-0649-9

    Article  PubMed  Google Scholar 

  50. Lesse GP, Fraser WD, Farquharson R, Hipkin L, Vora JP (1998) Gonadal status is an important determinant of bone density in acromegaly. Clin Endocrinol (Oxf) 48:59–65 Medline. doi:10.1046/j.1365-2265.1998.00349.x

    Article  CAS  Google Scholar 

  51. Tutuncu NB, Erbas T (2004) Factors associated with bone metabolism in acromegalic patients: hypogonadism and female gender. Exp Clin Endocrinol Diabetes 112:328–332 Medline. doi:10.1055/s-2004-820913

    Article  PubMed  CAS  Google Scholar 

  52. Ueland T, Fougner SL, Godang K, Schreiner T, Bollerslev J (2006) Serum GH and IGF-I are significant determinants of bone turnover but not bone mineral density in active acromegaly: a prospective study of more than 70 consecutive patients. Eur J Endocrinol 155:709–715 Medline. doi:10.1530/eje.1.02285

    Article  PubMed  CAS  Google Scholar 

  53. Diamond T, Nery L, Posen S (1989) Spinal and peripheral bone mineral densities in acromegaly: the effects of excess growth hormone and hypogonadism. Ann Intern Med 111:567–573 Medline

    PubMed  CAS  Google Scholar 

  54. Jockenhovel F, Rohrbach S, Deggerich S, Reinwein D, Reiners C (1996) Differential presentation of cortical and trabecular peripheral bone mineral density in acromegaly. Eur J Med Res 1:377–382 Medline

    PubMed  CAS  Google Scholar 

  55. Parkinson C, Kassem M, Heickendorff L, Flyvbjerg A, Trainer PJ (2003) Pegvisomant-induced serum insulin-like growth factor-I normalization in patients with acromegaly returns elevated markers of bone turnover to normal. J Clin Endocrinol Metab 88:5650–5655 Medline. doi:10.1210/jc.2003-030772

    Article  PubMed  CAS  Google Scholar 

  56. Fairfield WP, Sesmilo G, Katznelson L et al (2002) Effects of a growth hormone receptor antagonist on bone markers in acromegaly. Clin Endocrinol (Oxf) 57:385–390 Medline. doi:10.1046/j.1365-2265.2002.01624.x

    Article  CAS  Google Scholar 

  57. Marazuela M, Astigarraga B, Tabuenca MJ, Estrada J, Marin F, Lucas T (1993) Serum bone Gla protein as a marker of bone turnover in acromegaly. Calcif Tissue Int 52:419–421 Medline. doi:10.1007/BF00571329

    Article  PubMed  CAS  Google Scholar 

  58. Piovesan A, Terzolo M, Reimondo G et al (1994) Biochemical markers of bone and collagen turnover in acromegaly or Cushing’s syndrome. Horm Metab Res 26:234–237 Medline

    Article  PubMed  CAS  Google Scholar 

  59. Vestergaard P, Mosekilde L (2004) Fracture risk is decreased in acromegaly–a potential beneficial effect of growth hormone. Osteoporos Int 15:155–159 Medline. doi:10.1007/s00198-003-1531-z

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Stanford University School of Medicine, 875 Blake Wilbur Drive, Stanford, CA, 94305-5826, USA

    Laurence Katznelson

Authors
  1. Laurence Katznelson
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Laurence Katznelson.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Katznelson, L. Alterations in body composition in acromegaly. Pituitary 12, 136–142 (2009). https://doi.org/10.1007/s11102-008-0104-8

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11102-008-0104-8

Keywords

Search

Navigation